FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely pharmacology and may be used for cerebral protection in treating cerebral affections. That is ensured by using Zongorine as a cerebroprotective agent.
EFFECT: agent provides the cerebroprotective action and prevents the death in animals suffering experimental post-hypoxic encephalopathy due to the activation of cerebral neutral stem cells.
2 ex, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
CEREBROPROTECTIVE AGENT | 2013 |
|
RU2517282C1 |
CEREBROPROTECTIVE AGENT | 2012 |
|
RU2497540C1 |
TISSUE REGENERATION STIMULATING AGENT | 2013 |
|
RU2599289C2 |
MEDICATION POSSESSING HAEMOSTIMULATING, ANTIMUTAGENIC, ANTITUMOUR, CEREBROPROTECTIVE, ANTIHYPOXIC, NOOTROPIC, ANXIOLYTIC AND ANTINEUROTIC ACTION | 2010 |
|
RU2438691C1 |
AN ANTIHYPOXIC AGENT | 1996 |
|
RU2121357C1 |
METHOD FOR CARRYING OUT EXPERIMENTAL ENCEPHALOPATHY THERAPY | 2004 |
|
RU2284060C1 |
AGENT SHOWING NOOTROPIC AND ADAPTOGENIC EFFECT | 1998 |
|
RU2136292C1 |
METHOD FOR CONTROLLING ERYTHROPOIESIS DISORDERS IN EXPERIMENTAL ENCEPHALOPATHY CASES | 2005 |
|
RU2302664C2 |
MEDICATION FOR REGENERATIVE MEDICINE | 2009 |
|
RU2406528C2 |
ANTIHYPOXIC AGENT | 2009 |
|
RU2392956C1 |
Authors
Dates
2013-12-20—Published
2012-11-01—Filed